Hydroxychloroquine

BreastfeedingPediatric

See adverse reactions attributed to class:

Antimalarial

COVID-19 putative drug

Acute febrile neutrophilic dermatosis (Sweet's syndrome) 

(2019): Bodard Q+, Rev Med Interne (French) Sep, Epub ahead of print (2 cases)

Acute generalized exanthematous pustulosis (AGEP) 

(2017): Duman H+, An Bras Dermatol 92(3), 404

(2016): Pearson KC+, Cutis 97(3), 212

(2015): Charfi O+, Indian J Pharmacol 47(6), 693

(2015): Ingen-Housz-Oro S+, Br J Dermatol 172(5), 1455

(2015): Yalcin B+, Ann Dermatol 27(4), 431 [REVIEW]

(2015): Zhang Z+, N Engl J Med 372(2), 161

(2014): Mokhtari F+, J Res Med Sci 19(8), 720 [REVIEW]25%

(2014): Sidoroff A, Hautarzt (German) 65(5), 430

(2013): Bailey K+, J Cutan Med Surg 17(6), 414 [REVIEW]

(2012): Fernando SL, Australas J Dermatol 53(2), 87 [REVIEW]

(2012): Sidoroff A, Chem Immunol Allergy 97, 139

(2010): Djennane M+, Rev Med Interne (French) 31(3), e7

(2010): Fain O+, Rev Prat (French) 60(1), 20

(2010): Park JJ+, Ann Dermatol 22(1), 102

(2009): Di Lernia V+, Clin Exp Dermatol 34 (8), e757

(2009): Lateef A+, Clin Rheumatol 28 (12), 1449Geriatric

(2008): Paradisi A+, Clin Ther 30(5), 930 [REVIEW] (3 cases)

(2004): Evans CC+, J Am Acad Dermatol 50(4), 650

(2003): Saissi EH+, Ann Dermatol Venereol 130(6-7), 612 [REVIEW]

(1996): Assier-Bonnet H+, Dermatology 193, 70 [REVIEW]

(1995): Bonnetblanc JM+, Ann Dermatol Venereol (French) 122, 604

(1995): Moreau A+, Int J Dermatol 34, 263 (passim)

(1993): Assier H+, Ann Dermatol Venereol (French) 120, 848

Angioedema <1%

(package insert)

Atrophy 

(2001): Vassallo C+, Clin Exp Dermatol 26(2), 141 [REVIEW]

Bullous dermatitis 

(2008): Jian X+, Cutan Ocul Toxicol 27(1), 5 (2 cases)

(1995): Kutz DC+, Arthritis Rheum 38, 440

Dermatitis 

(1999): Meier H+, Hautarzt (German) 50, 665

Dermatomyositis 

(1994): Bloom BJ+, J Rheumatology 21, 2171

DRESS syndrome 

(2020): Grandolfo M+, Dermatol Ther May, Online ahead of print (1 case)

(2018): Randhawa A+, Scott Med J Jan, Epub ahead of print

(2008): Schmutz JL+, Ann Dermatol Venereol 135 (12)

(2008): Volpe A+, Clin Rheumatol 27 (4), 537

Ecchymoses 

(2013): Jallouli M+, JAMA Dermatol 149(8), 935

Erythema annulare centrifugum 

(1985): Hudson LD, Cutis 36(2), 129

(1982): Koralewski F, Dermatosen (German) 30, 125

(1967): Ashurst PJ, Arch Dermatol 95, 37

Erythema multiforme <1%

(2020): Koumaki D+, Clin Case Rep 8(3), 578 (1 case)

(2017): Abou Assalie N+, J Clin Rheumatol 23(2), 127

(2006): Perez-Ezquerra PR+, Allergol Immunopathol (Madr) 34(4), 174

Erythema nodosum 

(1996): Jarrett P+, Br J Dermatol 134, 373 (chronic)

Erythroderma 

(2017): Pai SB+, Indian J Pharmacol 49(1), 132

(1990): Simoneaux PW, Curr Concept Skin Dis Winter, 15

(1985): Slagel GA+, J Am Acad Dermatol 12, 857

Exanthems <5%

(2006): Perez-Ezquerra PR+, Allergol Immunopathol (Madr) 34(4), 174

(2001): Werth V, Dermatol Online J 7(1)

(1991): Ochsendorf FR+, Hautarzt (German) 42, 140

(1990): Simoneaux PW, Curr Concept Skin Dis Winter, 15

Exfoliative dermatitis 

(1986): Lavrijsen AP+, Acta Derm Venereol (Stockh) 66(6), 536

(1985): Slagel GA+, J Am Acad Dermatol 12, 857

(1981): Koranda FC, J Am Acad Dermatol 4(6), 650 [REVIEW] (passim)

Fixed eruption <1%

(package insert)

Hyperpigmentation 

(2019): Thakur V+, Postgrad Med J 95(1121), 169 (1 case)Geriatric

Lesions 

(2017): Matsuda T+, J Dermatol Dec, Epub ahead of print [REVIEW]

Lichen planus 

(1948): Craige B+, J Clin Invest 27(3 Pt 2), 56

Lichenoid eruption 

(1990): Simoneaux PW, Curr Concept Skin Dis Winter, 15

(1981): Koranda FC, J Am Acad Dermatol 4(6), 650 [REVIEW] (passim)

(1958): Savage J, Br J Dermatol 70(5), 181

(1948): Alving AS+, J Clin Invest 27(3 Pt 2), 60

Pemphigus 

(2006): Ghaffarpour G+, Int J Dermatol 45(10), 1261

Photoallergic reaction 

(2004): Lisi P+, Contact Dermatitis 50(4), 255

Photosensitivity 

(2005): Owens RC Jr+, Clin Infect Dis 41Suppl 2, S144

(2001): Metayer I+, Ann Dermatol Venereol 128(6), 729 (4 cases)

(1991): Ochsendorf FR+, Hautarzt (German) 42, 140

(1982): van Weelden H, Arch Dermatol 118, 290

(1981): Journet M, Union Med Can (French) 110(4), 356

(1968): Arch Dermatol 98(3), 327

Phototoxicity 

(2008): Callaly EL+, Clin Exp Dermatol 33(5), 572

(2004): Lisi P+, Contact Dermatitis 50(4), 255

(2001): Metayer I+, Ann Dermatol Venereol 128(6), 729 (4 cases)

Pigmentation <10%

(2019): Thakur V+, Postgrad Med J 95(1121), 169 (1 case)

(2017): Bahloul E+, Lupus 26(12), 1304 [REVIEW] (41 cases)

(2017): Ponticelli C+, Expert Opin Drug Saf 16(3), 411 [REVIEW]

(2016): van Nimwegen JF+, Expert Opin Drug Saf 15(4), 513 [REVIEW]

(2014): Rodriguez-Caruncho C+, Actas Dermosifiliogr 105(3), 243 [REVIEW]

(2013): Jallouli M+, JAMA Dermatol 149(8), 935

(2013): Tracy CL+, J Clin Rheumatol 19(5), 292

(2012): Cho EB+, J Dermatol 39(10), 859

(2008): Melikoglu MA+, J Clin Pharm Ther 33(6), 699 (bluish-grey to black)

(2008): Puri PK+, J Cutan Pathol 35(12), 1134

(2008): Rood MJ+, Scand J Rheumatol 37(2), 158

(2007): Amichai B+, J Clin Rheumatol 13(2), 113

(2006): Reynaert S+, J Eur Acad Dermatol Venereol 20(4), 487

(2005): Fardet L+, Ann Dermatol Venereol 132(8-9 Pt 1), 665 [REVIEW]

(2004): Millard TP+, Clin Exp Dermatol 29(1), 92

(1991): Ochsendorf FR+, Hautarzt (German) 42, 140

(1982): Levy H, S Afr Med J 2, 735

(1981): Koranda FC, J Am Acad Dermatol 4(6), 650 [REVIEW] (passim)

(1963): Tuffanelli D+, Arch Dermatol 88, 419

(1959): Dall JL+, Br Med J 1(5134), 1387

Pruritus >10%

(2017): Ponticelli C+, Expert Opin Drug Saf 16(3), 411 [REVIEW]

(2006): Gul U+, Eur J Dermatol 16(5), 586

(2006): Perez-Ezquerra PR+, Allergol Immunopathol (Madr) 34(4), 174

(2004): Jimenez-Alonso J+, Rev Clin Esp 204(11), 5882%

(1999): Holme SA+, Acta Derm Venereol (Stockh) 79, 333

(1994): Fain O+, Rev Med Interne (French) 15, 433

(1991): Mnyika KS+, J Trop Med Hyg 94, 2747%

(1990): Abdulkadir SA+, Trans Roy Soc Trop Med Hyg 84, 898

(1990): Simoneaux PW, Curr Concept Skin Dis Winter, 15

(1984): Osifo NG, Arch Dermatol 120, 80

(1982): Spencer HC+, BMJ 285, 1703

(1969): Olatunde IA, J Nigerian Med Assoc 6, 23

(1964): Ekpechi OL+, Arch Dermatol 120, 80

Psoriasis 

(exacerbation)

(2020): Sachdeva M+, J Am Acad Dermatol May, Online ahead of print [REVIEW]28%

(2019): Ullah A+, BMJ Case Rep 12(2), bcr-2018-224619 (1 case)

(2018): Wang WM+, Chin Med J (Engl) 131(15), 1887 (1 case)

(2017): Balak DM+, Psoriasis (Auckl) 7, 87 [REVIEW]

(2017): Ponticelli C+, Expert Opin Drug Saf 16(3), 411 [REVIEW]

(2015): Seminario-Vidal L+, Skinmed 13(6), 492 (new onset)

(2003): Welsch MJ, J Drugs Dermatol 2, 193

(1996): Vine JE+, J Dermatol 23, 357

(1993): Potter B, Cutis 52, 229 (passim)

(1988): Nicolas J-F+, Ann Dermatol Venereol (French) 115, 289

(1987): Friedman SJ, J Am Acad Dermatol 16, 1256

(1985): Gray RG, J Rheumatol 12, 391

(1982): Abel EA+, J Am Acad Dermatol 15, 2007

(1982): Luzar MJ, J Rheumatol 9, 462

(1981): Olsen TG, Ann Intern Med 94, 546

(1966): Baker H, Br J Dermatol 78(5), 249

(1957): Cornbleet T+, Arch Dermatol 75, 286

Pustules 

(1990): Lotem M+, Acta Derm Venereol (Stockh) 70, 250

Rash <10%

(2016): van Nimwegen JF+, Expert Opin Drug Saf 15(4), 513 [REVIEW]

(2013): Carnovale C+, J Clin Pharm Ther 38(2), 169

(2006): Mates M+, J Rheumatol 33(4), 814

(2001): Levy RA+, Lupus 10(6), 401

Stevens-Johnson syndrome 

(2002): Leckie MJ+, Rheumatology (Oxford) 41(4), 473

Telangiectasia 

(2001): Vassallo C+, Clin Exp Dermatol 26(2), 141 [REVIEW]

Thrombocytopenic purpura 

(2011): Mar N+, J Thromb Thrombolysis 31(1), 119

(1994): Caminal Montero L+, An Med Interna 11(6), 310

Toxic epidermal necrolysis 

(2009): Lateef A+, Clin Rheumatol 28 (12), 1449Geriatric

(2008): Callaly EL+, Clin Exp Dermatol 33(5), 572 (photo-induced)

(2001): Murphy M+, Clin Exp Dermatol 26(5), 457 (fatal)Fatal

Toxicity 

(2015): Al-Bari MA, J Antimicrob Chemother 70(6), 1608 [REVIEW]

Urticaria 

(1990): Simoneaux PW, Curr Concept Skin Dis Winter, 15

(1981): Koranda FC, J Am Acad Dermatol 4(6), 650 [REVIEW] (passim)

Vasculitis 

(2003): Welsch MJ, J Drugs Dermatol 2(2), 193

Alopecia 

(2017): Ponticelli C+, Expert Opin Drug Saf 16(3), 411 [REVIEW]

(2016): van Nimwegen JF+, Expert Opin Drug Saf 15(4), 513 [REVIEW] (transient)

Hair pigmentation <10%

(bleaching)

(2017): Ponticelli C+, Expert Opin Drug Saf 16(3), 411 [REVIEW]

(1999): Lecocq P+, Presse Med (French) 28, 741

(1991): Ochsendorf FR+, Hautarzt (German) 42, 140

(1985): Arch Dermatol 121, 1164

(1981): Koranda FC, J Am Acad Dermatol 4(6), 650 [REVIEW] (passim)

(1978): Dubois EL, Semin Arthritis Rheum 8, 33 [REVIEW]

(1976): Sams WM, Int J Dermatol 15, 99 [REVIEW]

(1965): Rook A, Br J Dermatol 77, 115

Discoloration 

(1991): Zic JA+, Arch Dermatol 127, 1037

Nail pigmentation 

(2001): Vassallo C+, Clin Exp Dermatol 26(2), 141 [REVIEW]

(1981): Koranda FC, J Am Acad Dermatol 4(6), 650 [REVIEW] (passim)

(1963): Tuffanelli D+, Arch Dermatol 88, 419

Onychocryptosis 

(1995): Sibilia J+, Rev Rhum Engl Ed 62(11), 795 (psoriatic)

Mucosal atrophy 

(2001): Vassallo C+, Clin Exp Dermatol 26(2), 141 [REVIEW]

Oral pigmentation 

(2012): Kalampalikis A+, J Dtsch Dermatol Ges 10(12), 921

(2005): Fardet L+, Ann Dermatol Venereol 132(8-9 Pt 1), 665 [REVIEW]

(2001): Vassallo C+, Clin Exp Dermatol 26(2), 141 [REVIEW]

(1992): Veraldi S+, Cutis 49, 281

(1991): Zic JA+, Arch Dermatol 127, 1037

(1981): Koranda FC, J Am Acad Dermatol 4(6), 650 [REVIEW] (passim)

(1971): Giansanti JS+, Oral Surg Oral Med Oral Pathol 31(1), 66

Stomatitis 

(2016): Patel S+, Oncotarget 7(37), 59087 (with vorinostat)

(2001): Vassallo C+, Clin Exp Dermatol 26(2), 141 [REVIEW]

Cardiomyopathy 

(2018): Dogar MU+, Postgrad Med J 94(1109), 185 (1 case)

(2016): Tselios K+, J Clin Rheumatol 22(5), 287

(2014): Yogasundaram H+, Can J Cardiol 30(12), 1706 [REVIEW]

(2012): Azimian M+, J Clin Rheumatol 18(7), 363 (fatal / 2 cases)Fatal

(2012): Bae SM+, Cardiology 123(3), 197

(2012): Frustaci A+, Int J Cardiol 157(1), 117

(2012): Sumpter MD+, Lupus 21(14), 1594

(2011): Muthukrishnan P+, Circ Heart Fail 4(2), e7

(2009): Manohar VA+, J Rheumatol 36(2), 440

Cardiotoxicity 

(2017): Ponticelli C+, Expert Opin Drug Saf 16(3), 411 [REVIEW]

(2012): Abbasi S+, J Am Coll Cardiol 60(8)

(2012): Tang C+, Intern Med J 42(9), 968

(2005): Keating RJ+, J Am Soc Echocardiogr 18(9), 981

Myocardial toxicity 

(2004): Nord JE+, Semin Arthritis Rheum 33(5), 336 [REVIEW]

QT prolongation 

(2020): Mercuro NJ+, JAMA Cardiol May, Online ahead of print

(2020): Tomcsányi J+, Orv Hetil (Hungarian) 161(17), 689-691 [REVIEW]

(2014): Mancano MA, Hosp Pharm 49(4), 329

(2013): Morgan ND+, J Clin Rheumatol 19(5), 286

(2006): Chen CY+, Clin Toxicol (Phila) 44(2), 173

Torsades de pointes 

(2006): Chen CY+, Clin Toxicol (Phila) 44(2), 173

Ventricular arrhythmia 

(2020): Mehra MR+, Lancet May, Online ahead of print6%

(2006): Chen CY+, Clin Toxicol (Phila) 44(2), 173

Ageusia (taste loss) 

(2009): Fleury O+, J Eur Acad Dermatol Venereol 23(5), 604 (reversible)

Anorexia 

(2016): Patel S+, Oncotarget 7(37), 59087 (with vorinostat)

(2014): Rangwala R+, Autophagy 10(8), 136928% (with temozolomide)

Dysgeusia (taste perversion) 

(2004): Jimenez-Alonso J+, Rev Clin Esp 204(11), 58864%

(1996): Weber JC+, Presse Med (French) 25, 213

Hallucinations 

(2004): Ferraro V+, Ann Dermatol Venereol 131(5), 471

Headache 

(2017): Ponticelli C+, Expert Opin Drug Saf 16(3), 411 [REVIEW]

(2013): Carnovale C+, J Clin Pharm Ther 38(2), 169

Memory loss/memory impaired 

(2017): Feng SW+, J Clin Rheumatol Dec, Epub ahead of print (reversible)

Nervousness 

(2018): Mascolo A+, Inflammopharmacology Jun, Epub ahead of print [REVIEW] (passim)

Neurotoxicity 

(2015): Gonzalez-Nieto JA+, Lupus 24(3), 339

(2014): Yogasundaram H+, Can J Cardiol 30(12), 1706 [REVIEW]

(2012): Tang C+, Intern Med J 42(9), 968

Nightmares 

(2004): Ferraro V+, Ann Dermatol Venereol 131(5), 471

Peripheral neuropathy 

(2017): Ponticelli C+, Expert Opin Drug Saf 16(3), 411 [REVIEW]

Psychosis 

(2018): Mascolo A+, Inflammopharmacology Jun, Epub ahead of print [REVIEW] (passim)

Seizures 

(2000): Malcangi G+, Rheumatol Int 20(1), 31

Suicidal ideation 

(2018): Mascolo A+, Inflammopharmacology Jun, Epub ahead of print [REVIEW] (passim)

Vertigo (dizziness) 

(2017): Ponticelli C+, Expert Opin Drug Saf 16(3), 411 [REVIEW]

Appetite decreased 

(2017): Ponticelli C+, Expert Opin Drug Saf 16(3), 411 [REVIEW]

Creatine phosphokinase increased 

(2014): Mahalingam D+, Autophagy 10(8), 1403 (with vorinostat)

Hypoglycemia 

(2020): Dai Y+, Clin Ther Apr, Epub ahead of print (serious / 1 case)

(2018): El-Solia A+, BMJ Case Rep Apr, Epub

(2011): Unubol M+, J Clin Rheumatol 17(1), 46

(2011): Winter EM+, BMJ Case Rep Oct, Epub

(2008): Cansu DU+, Rheumatology (Oxford) 47(3), 378

Porphyria 

(1993): Potter B, Cutis 52, 229 (passim)

(1976): Baler GR, Cutis 17, 96

(1974): Kordac V+, Br J Dermatol 90, 95

(1962): Cripps DL+, Arch Dermatol 86, 575

(1959): Marsden CW, Br J Dermatol 71(6), 219

(1957): Davis MJ+, AMA Arch Derm 75(6), 769

(1954): Linden IH+, Calif Med 81(3), 235

Weight loss 

(2016): Patel S+, Oncotarget 7(37), 59087 (with vorinostat)

(2014): Mahalingam D+, Autophagy 10(8), 1403 (with vorinostat)

Abdominal pain 

(2017): Ponticelli C+, Expert Opin Drug Saf 16(3), 411 [REVIEW]

Constipation 

(2014): Rangwala R+, Autophagy 10(8), 136920% (with temozolomide)

Diarrhea 

(2020): Tang W+, BMJ 369, m184910%

(2017): Ponticelli C+, Expert Opin Drug Saf 16(3), 411 [REVIEW]

(2016): Patel S+, Oncotarget 7(37), 59087 (with vorinostat)

(2014): Mahalingam D+, Autophagy 10(8), 1403 (with vorinostat)

(2014): Rangwala R+, Autophagy 10(8), 136920% (with temozolomide)

(2014): Rodriguez-Caruncho C+, Actas Dermosifiliogr 105(3), 243 [REVIEW]

Dysphagia 

(2007): Mateen FJ+, Can J Neurol Sci 34(3), 377 (severe) (reversible)

(2007): Mateen FJ+, Can J Neurol Sci 34(3), 377

Hepatotoxicity 

(2018): Sunkara B+, Lupus 27(8), 1383 (1 case) (dose-related hepatotoxicity)

(2017): Ponticelli C+, Expert Opin Drug Saf 16(3), 411 [REVIEW]

Nausea 

(2017): Ponticelli C+, Expert Opin Drug Saf 16(3), 411 [REVIEW]

(2016): Patel S+, Oncotarget 7(37), 5908765% (with vorinostat)

(2014): Mahalingam D+, Autophagy 10(8), 1403 (with vorinostat)

(2014): Rangwala R+, Autophagy 10(8), 136948% (with temozolomide)

(2014): Rodriguez-Caruncho C+, Actas Dermosifiliogr 105(3), 243 [REVIEW]

(2013): Carnovale C+, J Clin Pharm Ther 38(2), 169

Vomiting  

(2017): Ponticelli C+, Expert Opin Drug Saf 16(3), 411 [REVIEW]

(2016): Patel S+, Oncotarget 7(37), 5908765% (with vorinostat)

(2014): Rodriguez-Caruncho C+, Actas Dermosifiliogr 105(3), 243 [REVIEW]

(2013): Carnovale C+, J Clin Pharm Ther 38(2), 169

Urinary incontinence 

(2013): Carnovale C+, J Clin Pharm Ther 38(2), 169

Anemia 

(2016): Patel S+, Oncotarget 7(37), 5908775% (with vorinostat)

(2014): Mahalingam D+, Autophagy 10(8), 1403 (with vorinostat)

(2011): Mar N+, J Thromb Thrombolysis 31(1), 119

Leukopenia (leukocytopenia) 

(2016): Patel S+, Oncotarget 7(37), 59087 (with vorinostat)

Myelodysplastic syndrome 

(2007): Muslimani AA+, Ann Hematol 86(7), 531 (4 cases)

Neutropenia 

(2016): Patel S+, Oncotarget 7(37), 59087 (with vorinostat)

(2014): Rosenfeld MR+, Autophagy 10(8), 1359 (with temozolomide and radiation therapy)

Sepsis 

(2014): Rosenfeld MR+, Autophagy 10(8), 1359 (with temozolomide and radiation therapy)

Thrombocytopenia 

(2017): Anton Vazquez V+, Reumatol Clin 13(5), 294

(2016): Patel S+, Oncotarget 7(37), 5908740% (with vorinostat)

(2014): Rosenfeld MR+, Autophagy 10(8), 1359 (with temozolomide and radiation therapy)

(2011): Mar N+, J Thromb Thrombolysis 31(1), 119

Asthenia (fatigue) 

(2016): Patel S+, Oncotarget 7(37), 5908755% (with vorinostat)

(2014): Mahalingam D+, Autophagy 10(8), 1403 (with vorinostat)

(2014): Rangwala R+, Autophagy 10(8), 136955% (with temozolomide)

Myalgia/Myositis/Myopathy/Myotoxicity 

(2018): Khosa S+, Neuropathology 38(6), 646 (4 cases)

(2013): Priori R+, J Clin Rheumatol 19(3), 132

(2010): Kwon JB+, J Clin Rheumatol 16 (1), 28

(2009): Lonesky TA+, J Rheumatol 36(11), 2617

(2008): Abdel-Hamid H+, Muscle Nerve 38(3), 1206 (fatal / 2 cases)Fatal

(2007): Mateen FJ+, Can J Neurol Sci 34(3), 377

(2007): Siddiqui AK+, Chest 131 (2), 588

(1998): Richards AJ, J Rheumatol 25, 1642

(1969): Chapman RS+, Br J Dermatol 81, 217

Rhabdomyolysis 

(2005): Creel N+, J Drugs Dermatol 4(2), 225 (with quinacrine)

Corneal deposits 

(2014): Rodriguez-Caruncho C+, Actas Dermosifiliogr 105(3), 243 [REVIEW]5%

Diplopia (double vision) 

(1997): Sabbagh M, Rev Rhum Engl Ed 64(1), 65

Macular edema 

(2017): Chang CY+, Taiwan J Ophthalmol 7(1), 56

Maculopathy 

(2016): van Nimwegen JF+, Expert Opin Drug Saf 15(4), 513 [REVIEW]

(2012): Rodriguez-Hurtado FJ+, Reumatol Clin 8(5), 280

(2007): Santaella RM+, Drugs 67(1), 75

(2001): Warner AE, Arthritis Rheum 44(8), 1959

(1985): Taylor F, Aust Fam Physician 14(8), 744

Ocular adverse effect 

(2014): Miguel A+, Pharmacoepidemiol Drug Saf 23(3), 221 [REVIEW]

(2006): Elder M+, Arch Ophthalmol 124(12), 17297%

Ocular toxicity 

(2017): Ponticelli C+, Expert Opin Drug Saf 16(3), 411 [REVIEW]

(2015): Rodriguez-Hurtado FJ+, Reumatol Clin 11(3), 170

(2015): Tandon VR+, Indian J Med Res 142(1), 33

(2013): Browning DJ, Am J Ophthalmol 155(3), 418

(2012): Marmor MF, Arch Ophthalmol 130(4), 461

(2012): Pulido JS+, Ophthalmology 119(1), 207

(2008): Tehrani R+, Semin Ophthalmol 23(3), 201 [REVIEW]

(2006): Yam JC+, Hong Kong Med J 12(4), 294 [REVIEW]

(2002): Grana Gil+, An Med Interna 19(4), 189

Reduced visual acuity 

(2006): Elder M+, Arch Ophthalmol 124(12), 17292%

(2006): Yam JC+, Hong Kong Med J 12(4), 294 [REVIEW]

Retinal detachment 

(2012): Lee WJ+, Cutan Ocul Toxicol 31(2), 144

Retinopathy 

(2018): Abdulaziz N+, Curr Opin Rheumatol 30(3), 249 [REVIEW]

(2018): Tetu P+, Ann Dermatol Venereol May, Epub ahead of print (3 cases)

(2017): Gianfrancesco MA+, Rheumatol Int 37(10), 1611

(2017): Ponticelli C+, Expert Opin Drug Saf 16(3), 411 [REVIEW]

(2016): Bourgeois N+, Therapie (French) 71(4), 365

(2016): Ragan A+, CMAJ Jul, Epub ahead of print

(2015): Costedoat-Chalumeau N+, Clin Rev Allergy Immunol 49(3), 317 [REVIEW]

(2015): Mehta A+, Indian J Dermatol 60(3), 230 [REVIEW]

(2015): Melles RB+, Ophthalmology 122(1), 110 [REVIEW]

(2014): Chiang E+, Rheumatology (Oxford) 53(11), 2001

(2014): Melles RB+, JAMA Ophthalmol 132(12), 1453

(2014): Yogasundaram H+, Can J Cardiol 30(12), 1706 [REVIEW]

(2013): Carnovale C+, J Clin Pharm Ther 38(2), 169

(2012): Adam MK+, Br J Ophthalmol 96(5), 723

(2012): Costedoat-Chalumeau N+, Rev Med Interne 33(5), 265

(2012): Lee WJ+, Cutan Ocul Toxicol 31(2), 144

(2012): Tang C+, Intern Med J 42(9), 968

(2011): Michaelides M+, Arch Ophthalmol 129(1), 30

(2011): Payne JF+, Br J Ophthalmol 95(2), 245

(2010): Wolfe F+, Arthritis Care Res (Hoboken) 62 (6), 775

(2009): Stepien KE+, Trans Am Ophthalmol Soc 107, 28

(2008): Nencini C+, Eur Rev Med Pharmacol Sci 12(5), 293 [REVIEW]

(2008): Tehrani R+, Semin Ophthalmol 23(3), 201 [REVIEW]

(2007): Ferreras A+, Arch Soc Esp Oftalmol 82(2), 103

(2006): Ingster-Moati I+, J Fr Ophtalmol (French) 29(6), 642

(2006): Tripp JM+, Am J Clin Dermatol 7(3), 171 [REVIEW]

(2006): Yam JC+, Hong Kong Med J 12(4), 294 [REVIEW]

(2005): Fardet L+, Ann Dermatol Venereol 132(8-9 Pt 1), 665 [REVIEW]

(2005): Lai TY+, Am J Ophthalmol 140(5), 794

(2005): Tzekov R, Doc Ophthalmol 110(1), 111 [REVIEW]

(2004): Constable S+, Expert Opin Drug Saf 3(3), 249 [REVIEW]

Vision blurred 

(2016): Patel S+, Oncotarget 7(37), 59087 (with vorinostat)

(2016): van Nimwegen JF+, Expert Opin Drug Saf 15(4), 513 [REVIEW]

(2006): Yam JC+, Hong Kong Med J 12(4), 294 [REVIEW]

Vision loss 

(2006): Yam JC+, Hong Kong Med J 12(4), 294 [REVIEW]

Hearing loss 

(2017): Chatelet JN+, Rev Med Interne (French) 38(5), 340

(2007): Bortoli R+, Clin Rheumatol 26 (11), 1809

Ototoxicity 

(2011): Lim SC+, Int J Rheum Dis 14(1), e1Pediatric

Tinnitus 

(2017): Ponticelli C+, Expert Opin Drug Saf 16(3), 411 [REVIEW]

Nephrotoxicity 

(2018): Sperati CJ+, Kidney Int 94(3), 634 (1 case)

Podocytopathy 

(2019): Serre J+, BMJ Case Rep 12(5), e228876

Renal phospholipidosis 

(2019): Wu SZ+, World J Clin Cases 7(24), 4377 (1 case)

Eosinophilic pneumonia  

(2019): Ishiguro Y+, J Dermatol 46(10), e356 (1 case)

Adverse effects 

(2020): Patil VM+, Life Sci May, Online ahead of print [REVIEW]

(2018): Tetu P+, Ann Dermatol Venereol (French) 145(6-7), 39550%

(2017): Brealey J+, Ultrastruct Pathol 41(1), 124 (phospholipidosis)

(2017): Nic Dhonncha E+, Dermatol Ther 30(3), Epub [REVIEW]

(2017): Seth S+, J Allergy Clin Immunol Pract 5(1), 16516% (mild)

(2014): Gottenberg JE+, JAMA 312(3), 249

(2014): Machado-Alba JE+, Rev Panam Salud Publica 36(6), 396

(2013): Khubchandani SR+, Ultrastruct Pathol 37(2), 146 (phospholipidosis)

(2013): O'Dell JR+, N Engl J Med 369(4), 30777% (with methotrexate and sulfasalazine)

(2006): Elder M+, Arch Ophthalmol 124(12), 172911%

Death 

(2012): Azimian M+, J Clin Rheumatol 18(7), 363 (2 cases)

(2008): Abdel-Hamid H+, Muscle Nerve 38(3), 1206

(2001): Murphy M+, Clin Exp Dermatol 26(5), 457



Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of hydroxychloroquine in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Adverse reactions attributed to entire drug class Antimalarial

Hypersensitivity 

(2011): Singalavanija S+, J Med Assoc Thai 94 Suppl 3, S852%

Pigmentation 

(2016): Krause W, G Ital Dermatol Venereol 151(6), 694 [REVIEW]

(2013): Janier M, Ann Dermatol Venereol (French) 140 Suppl 3, s237

(2013): Krause W, J Dtsch Dermatol Ges 11(7), 644 [REVIEW]

QT prolongation 

(2010): Bril F+, Curr Drug Saf 5 (1), 85

Ocular toxicity 

(2014): Schneider C+, Travel Med Infect Dis 12(1), 40

(2013): Audo I, Rev Prat (French) 63(1), 63 [REVIEW]

Adverse reactions attributed to entire drug class COVID-19 putative drug

Cutaneous adverse reaction  

(2020): Tursen U+, Dermatol Ther May, Epub ahead of print [REVIEW]

Cardiovascular adverse effect 

(2020): Carpenter A+, Front Cardiovasc Med 7, 85 [REVIEW]

(2020): Giudicessi JR+, Mayo Clin Proc May, Online ahead of print [REVIEW]

(2020): Naksuk N+, Eur Heart J Acute Cardiovasc Care May, Epub ahead of print [REVIEW]

(2020): Sarayani A+, Res Social Adm Pharm Apr, Epub ahead of print [REVIEW]

Gastrointestinal disorder 

(2020): Sun J+, Clin Pharmacol Ther Apr, Epub ahead of print23%

Hepatic disorder 

(2020): Sun J+, Clin Pharmacol Ther Apr, Epub ahead of print14%

Thrombocytopenia 

(2020): Nham E+, Infect Chemother Apr, Epub ahead of print

Adverse effects 

(2020): Patil VM+, Life Sci May, Epub ahead of print [REVIEW]

(2020): Sun J+, Clin Pharmacol Ther Apr, Epub ahead of print38%

(2020): Svensson M, Lakartidningen (Swedish) Apr, 117

(2020): Wen CY+, Zhonghua Nei Ke Za Zhi (Chinese) May, Epub ahead of print

(2020): Zhong H+, Pharmacol Res Apr, Epub ahead of print [REVIEW]

Page last updated 05/27/2020

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top